Cytokinetics (CYTK) said Tuesday it is enrolling patients in a phase 3 trial designed to evaluate the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.

The trial is expected to randomize about 1,800 patients on a 1:1 basis to receive omecamtiv mecarbil or placebo, the company said.

Cytokinetics is conducting the trial in collaboration with the Duke Clinical Research Institute.